Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.41 |
| ▸ | JAK3 | P52333 | 8/20 | 0.41 |
| ▸ | JAK1 | P23458 | 5/20 | 0.41 |
| ▸ | TYK2 | P29597 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.36 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30213789 | 0.77 | PRKCI (0.46) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL17495401 | 0.77 | PRKCI (0.46) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL22941677 | 0.77 | JAK2 (0.43) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL29486783 | 0.77 | PRKCI (0.54) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL1935167 | 0.77 | PRKCI (0.54) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL31431566 | 0.74 | ALDH1A1 (0.41) | ALDH1A1RAB9ACTSB | |
| SCHEMBL17963822 | 0.73 | JAK2 (0.54) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL14795009 | 0.73 | JAK2 (0.43) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL12563092 | 0.73 | NUDT1 (0.44) | JAK2JAK3JAK1AXLPRKCI | |
| SCHEMBL12563109 | 0.73 | PRKCI (0.49) | JAK2JAK3JAK1TYK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688890-B1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-08-30 | — | — | EP | claimed |
| US-9115133-B2 | Substituted fused tricyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (US) | 2015-08-25 | — | — | US | claimed |
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD. | 2014-01-23 | — | — | US | claimed |
| EP-2688890-B1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-08-30 | — | — | EP | disclosed |
| US-9115133-B2 | Substituted fused tricyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115133-B2 | Substituted fused tricyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115133-B2 | Substituted fused tricyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD. | 2014-01-23 | — | — | US | disclosed |
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD. | 2014-01-23 | — | — | US | disclosed |
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD. | 2014-01-23 | — | — | US | disclosed |
| WO-2012127506-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | MALT1, JAK1, ICOS | JAK2 5/4885JAK3 6/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.